Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Lock-Up Period To End on January 15th

Artiva Biotherapeutics’ (NASDAQ:ARTV) lock-up period is set to expire on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its initial public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. After the end of Artiva Biotherapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analysts Set New Price Targets

A number of brokerages have commented on ARTV. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $21.00.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock opened at $10.58 on Wednesday. The firm has a 50-day moving average price of $11.37. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, equities research analysts anticipate that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth $166,000. Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics in the third quarter worth about $7,435,000. Barclays PLC purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $304,000. Geode Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $4,774,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.